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High instances of antimicrobial resistance are linked to both routine and excessive antimicrobial use, but excessive or inappro-
priate use represents an unnecessary risk. The competitive growth advantages of resistant bacteria may be amplified by the strain
dynamics; in particular, the extent to which resistant strains outcompete susceptible strains under antimicrobial pressure may
depend not only on the antimicrobial treatment strategies but also on the epidemiological parameters, such as the composition
of the bacterial strains in a pig. This study evaluated how variation in the dosing protocol for intramuscular administration of
tetracycline and the composition of bacterial strains in a pig affect the level of resistance in the intestine of a pig. Predictions
were generated by a mathematical model of competitive growth of Escherichia coli strains in pigs under specified plasma concen-
tration profiles of tetracycline. All dosing regimens result in a clear growth advantage for resistant strains. Short treatment dura-
tion was found to be preferable, since it allowed less time for resistant strains to outcompete the susceptible ones. Dosing fre-
quency appeared to be ineffective at reducing the resistance levels. The number of competing strains had no apparent effect on
the resistance level during treatment, but possession of fewer strains reduced the time to reach equilibrium after the end of treat-
ment. To sum up, epidemiological parameters may have more profound influence on growth dynamics than dosing regimens
and should be considered when designing improved treatment protocols.
Although the phenomenon of antimicrobial resistance is wellestablished, its persistent increase and alarming proportions
continue to threaten the ability of antimicrobials to treat infec-
tions. Antimicrobial exposure is an important driver of high re-
sistance levels. Decline in the development of new antibiotics calls
for optimal use of the available drugs. Antimicrobial usage in food
production animals contributes significantly to increased antimi-
crobial resistance in these animals (1). The reduced use of antimi-
crobials can reduce the resistance load; however, treatment of in-
fection is necessary to ensure a sufficient level of animal welfare
and health. Antimicrobials aremainly used treat infections caused
by pathogenic bacteria, but knowledge of the mobile genetics of
antimicrobial resistance has resulted in an expanding focus on
bacterial ecology. For pathogens, the normal commensal bacterial
flora within the animal is of interest as a potential genetic partner
in the transmission of antibiotic resistance genes (2). Several
classes of antimicrobials, such as -lactams, aminoglycosides, tet-
racyclines, and sulfonamides, are used in both human and veter-
inary medicine (3). Therefore, the development of antimicrobial
resistance in livestock is of public health concern due to the risk of
transmission of resistant zoonotic, as well as commensal, bacteria
to humans through the food chain.
It is unrealistic and unethical to stop antimicrobial use in in-
tensive pig production, where the pig sector accounted for ca. 80%
of the veterinary use of antibiotics in Denmark in 2012, with tet-
racycline being the most frequently used drug (3–5). Tetracycline
is commonly used against intestinal diseases in weaning pigs, both
metaphylactically and therapeutically in Denmark (5). Metaphy-
lactic use of antimicrobial agents is defined as the pen treatment of
both clinically ill and healthy animals, whereas therapeutic use is
defined as the prescription of antibiotics to a diagnosed clinically
ill animal. Therapeutic treatments with tetracycline are often via
intramuscular (i.m.) injection, whereas metaphylactic delivery is
commonly via food or water medication of the pen. Farmer and
veterinarians decide the treatment method after consultation de-
pending on the different factors, wheremetaphylactic treatment is
possible and legal only if 25%of the total pigs in a section of a herd
are sick (6). In this regard, therapeutic treatment has the advan-
tage over metaphylactic treatment of treating sick animals only.
Tetracyclines have been known for decades to lead to widespread
antimicrobial resistance among bacteria in the intestines of pigs
(7). Tetracyclines are also used in humans, accounting for 11% of
the total consumption of antimicrobials in the primary health care
industry in Denmark in 2012 (5). Therefore, there is a need to
improve tetracycline dosing strategies to minimize resistance
without compromising treatment efficacy.
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Escherichia coli is one of the commensal bacteria used as an
indicator of antimicrobial resistance in animals, humans, and
food products, and it shows high potential transmission via the
food chain. For example, an antimicrobial-resistant strain of E.
coli has survived processing and chilling better than the parental
antimicrobial-sensitive strain (8–10). On average, 36% of de-
tected E. coli were tetracycline resistant in the Danish surveillance
on pigs in 2012 (5). This surveillance has shown consistently high
levels of tetracycline resistant E. coli in the past 5 years, indicating
that tetracycline-resistant E. coli are endemic in the pig produc-
tion.
In the last decade, pharmacokinetic (PK) and pharmacody-
namic (PD) models have been used to assess the development of
antimicrobial resistance. Mathematical modeling techniques are
frequently used to estimate resistance and assess drug efficacy
(11). Such models, based on in vitro and in vivo studies, allow
rapid analysis of dosing strategies to help overcome the problem
of the development and emergence of antimicrobial resistance
(12). Traditional methods for optimizing treatment strategies are
generally based on point estimates (e.g., theMIC, maximum drug
concentration [Cmax], and the area under the concentration time
curve [AUC]) (13–15). In contrast, recent models include the dy-
namics of both PK and PD processes over time, providing deeper
insight and a more accurate description of the impact of antimi-
crobial dosing strategies (16–21). However, these studies were
based on the in vitro growth of bacterial populations and were
limited to a few (sometimes only one) clinical bacterial strains
across the susceptible and resistant subpopulations, providing a
poor reflection of the within host bacterial dynamics.
Recently, mathematical models have been used to simulate in
vivo scenarios that either are not possible, too expensive, or too
time-consuming in practice to assess the impact of dosing factors
(e.g., duration, frequency, dose, etc.) on the growth of antimicro-
bial-resistant bacteria (22–24). These studies focused on the im-
pact of dosing factors on the total resistance level but did not
account for differences in the numbers of competing strains or the
composition of strains with different susceptibilities on the effect
of a given treatment strategy. Therefore, high and persistent levels
of tetracycline-resistant E. coli need to be addressed via the mod-
eling approaches that consider themultiple strain composition. In
the present study, we investigated not only the effect of dosing
factors but also the effect of strain composition and the number of
competing strains on the formulation of treatment strategies for
minimum growth of E. coli-resistant bacteria.
We attempted to optimize i.m. tetracycline treatment in order
to minimize the level of antimicrobial resistance to tetracycline in
a treated pig. Our primary objectives were to use a mathematical
model to (i) predict competitive growth of randomly selected E.
coli strains in a pig under drug exposure based on in vivo PK data
from tetracycline i.m. treatment, (ii) assess the optimum dosing
frequency and treatment duration to suppress or delay the growth
of resistant strains, and (iii) analyze the effect of both the compo-
sition and the number of competing strains on resistance levels.
MATERIALS AND METHODS
The model includes the growth of multiple strains under dynamic equi-
librium in a pig after i.m. treatment. The dynamic equilibrium of growing
strains was established by introducing a constant “outflow rate” into the
model. The growth of the strains in the model was affected by antimicro-
bial concentration and by the total bacterial count, whereas the antimi-
crobial concentration was dependent on a combination of dosing factors
(frequency, duration, etc.). The composition ofmultiple strains wasmade
by random selection of strains with growth characteristics determined in
vitro.
In vivo pharmacokinetics. The plasma concentrations of tetracycline
in pigs after i.m. treatmentweremodeled using data from the literature on
the plasma concentrations of oxytetracycline in pigs after administration
of the drug i.m. (25), where the plasma concentrations of oxytetracycline
were determined at different time points over 48 h after drug administra-
tion in 12 healthy pigs. A two-compartment PK model was fitted to the
mean values of the plasma concentration and time profile to estimate the
transfer rate parameters, as shown in Fig. 1 and equations 1, 2, and 3.
dCg
dt
kaCg (1)
dCc
dt
 kaCg k21Cp (k12 kel)Cc (2)
dCp
dt
 k12Cc k21 Cp (3)
These equations represent changes in drug concentrations, Cc and Cp,
over time in the central (plasma) and peripheral (tissue) compartments,
respectively, where ka is the drug absorption rate from diffusion compart-
mentCg, k12 and k21 are the transfer rates between the two compartments,
and kel is the elimination rate from the central compartment (Fig. 1). The
estimated rates (ka, k12, k21, and kel) were used to produce different con-
centration-time profiles for different combinations of treatment dura-
tions and dosing frequencies that deliver the same daily dose of 20 mg/kg.
Three treatment durations (3, 5, and 8 days) and three dosing frequencies
(once every 2 days, once per day, and twice per day) were selected, giving
a total of nine combinations of concentration profiles.
Growth parameters. The in vitro growth of 50 E. coli strains in the
presence of tetracycline were previously assessed using a PD Emax model
(A. Ahmad, C. Zachariasen, L. E. Christiansen, K. Græsbøll, N. Toft, L.
Matthews, P.Damborg, J. E.Olsen, Y. Agersø, and S. S.Nielsen, submitted
for publication). The relationship between the tetracycline concentration
(c) and the estimated net bacterial growth rates  was analyzed using the
model:
(c) max
max cEC50

1  cEC50
 (4)
where max is the bacterial growth rate in the absence of the drug (maxi-
mum effect), EC50 is the drug concentration at which the drug effect is
reduced to 50%, and  denotes the Hill coefficient, which is a measure of
the steepness of the sigmoid relationship between the concentration (c)
and the net growth rate at around EC50 (27). The estimatedmodel param-
FIG 1 Two-compartmental PK-model with central compartment being the
plasma compartment and peripheral compartment being tissue compartment.
ka is the first-order absorption rate as drug is being absorbed from intramus-
cular injection site Cg.
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eters (max, EC50, and ; see the supplemental material), which described
the growth response to the antimicrobial, were used to construct the
PK-PD model. These 50 E. coli strains were randomly selected from
among 160 porcine indicator E. coli isolates from the Danish Integrated
Antimicrobial ResistanceMonitoring andResearch Program (DANMAP)
in 2010 (28). A cutoff value of 8g/ml between susceptible and resistantE.
coli strains was also adopted from DANMAP 2010.
Mathematical model for competitive growth. We modeled the
changes in bacterial counts of individual bacterial strains in a pig using
growth parameters from the PD model combined with the in vivo drug
profile using an ordinary differential equation given by the following
equation:
dNi
dt
 max maxcEC50  cNmax NiNmax NmaxNiNmax Ni Ni
(5)
The left side of the equation shows the change in bacterial counts for
strain i (Ni). The first term in parentheses on the right side of the equation
gives the drug efficacy as a function of the three PD model parameters
(max, EC50, and ) and the in vivo drug concentration-time profile c. The
remaining parenthetic terms are density-dependent limitations to
growth, which depend on the carrying capacity, the Nmax, and the total
bacterial counts summed over all competing strains in the pig (Ni). The
final term is the excretion of strains from a pig with an outflow rate ()
(29).
Both the composition and the diversity of E. coli vary considerably
between pigs; up to 10 different E. coli strains were found in the intestinal
flora of healthy domestic pigs (30). To capture the effect of number of
competing strains on resistance levels, simulations were run with 12, 6,
and 3 strains. A plasma concentration profilewas used for bacterium-drug
interaction after i.m. injection because the plasma concentration is often
used as a surrogate for the concentration at the actual interaction site, in
this case the intestine (31).
The carrying capacity Nmax was set to 10
10 bacteria (23, 29, 32). An
outflow rate,, of 0.01 of strainswas taken froma published experimental
study that estimated this rate as the hourly fractional inflow and outflow
of E. coli “free-living” in the large intestine from an in vivo study in
postweaned dairy calves (22, 33). The model was initiated by selecting 12
strains with one-third resistant and assigning growth parameters to these
strains as described above. The model was initially run without drugs to
attain the dynamic equilibrium in the absence of selection pressures. Ini-
tial values of individual strains were randomly selected between 106 and
109, with the sum not exceeding the carrying capacity of 1010.
Treatment was introduced once the equilibrium with 12 E. coli com-
peting in the intestinal flora of a pig was attained, and the first treatment
day was denoted day 0. The 12 E. coli strains were randomly selected from
among the 50 E. coli strains representing the pig population of Denmark.
We considered the treatment of weaning pigs, since the proportion of
antimicrobial use is much higher in weaning pigs compared to finishers
and sows (5). Therefore, the model was allowed to run for a period of 35
days after treatment (a period during which the pig will leave the weaner
section) to assess the effect of dosing factors on growth dynamics and
resistance levels when pigs leaves the weaning section. To capture the
variation in growth characteristics and susceptibility levels in the mix of
strains, simulations were repeated 100 times, with the strains sampled
FIG 2 Tetracycline plasma concentration profiles for different combinations of dosing frequency (from left to right) and treatment duration (from top to
bottom), with the same per day dose (20 mg/kg) of i.m. injection treatment. The vertical dotted lines demarcate the treatment interval.
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randomly each time from the collection of 50 E. coli strains with known
growth characteristics. We report the mean with a simulation envelope of
the sum of susceptible and resistant strains for these 100 repetitions.
The procedure was repeated with treatment protocols based on differ-
ent combinations of dosing factors, as indicated in Fig. 2. To compare
across treatment protocols, the same strains and initial values were used.
Different numbers of competing strains (6 and 3) in a pig were also con-
sidered. Since ca. 30% of detected E. coli were tetracycline resistant in the
Danish surveillance of pigs in 2011, competing strains were selected with
one-third (33.3%) of them being resistant (5). Thus, in the competition
between 12, 6, and 3 strains, 4, 2, and 1 strains were found to be resistant,
respectively. The model was written in R version 3.0.1 for Windows
(“Frisbee Sailing”) (34); all data were also analyzed and plotted using R.
RESULTS
Concentration-time profiles. The plasma concentration profiles
Cc in a pig following an i.m. tetracycline treatment of 20 mg/kg/
day for different dosing combinations are shown in Fig. 2. An
increase in dosing frequency (Fig. 2, left to right) maintained the
concentration above a certain level, but also reduced the peak
concentration. Increasing the duration (Fig. 2, top to bottom) did
not increase the peak value, but extended the time above a thresh-
old concentration level. These concentration-time profiles (Fig. 2)
were fed into themodel (equation 5) and thus shape the treatment
strategy results. The maximum peak concentration attained in
these protocols was10 g/ml, which was far below the suscep-
tibility levels of resistant strains. As a result, all of the resistant
strains had a competitive advantage, irrespective of the treatment
protocols and their susceptibility levels.
Model outputs. A sample of 16 repetitions out of 100 per-
formed on 12 competing strains under the same treatment proto-
col (once a day for 5 days) is given in Fig. 3. The period prior to day
0 (when treatment started) was to allow a dynamic equilibrium to
be established in the absence of treatment. Dynamic equilibrium
in the present study refers to the coexistence of multiple strains in
a pig, where only small changes happen over long periods of time,
unless the system is disturbed by, e.g., an antimicrobial treatment.
After a disturbance, the system will again return to a state of equi-
librium,whichmay ormay not differ from the original one. In our
case, a dynamic equilibrium was only possible when	max for
all competing strains. If  was larger than the growth rates, then
the strains would all vanish with time. The dynamic equilibrium
was disrupted by the treatment, and it took various lengths of time
posttreatment to return to equilibrium (Fig. 3). All resistant
strains (red lines) among a total of 12 competing strains showed
clear growth advantages during the treatment period. This led to a
FIG 3 Example of competitive growth of 12 strains (lines) with 16 repeats (one per plot). In each repeat, 12 strains were drawn randomly from 50 strains, with
one-third of the total pool being resistant (red lines). Both the treatment duration (5 days) and the dosing frequency (once a day) are the same in all 16 plots. The
treatment window is demarcated with vertical lines.
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high resistant proportion at the end of treatment and time to
regain the dynamic equilibrium posttreatment (Fig. 3).
Repetitions performed for 12 competing strains under the
same treatment protocol showed a large variation in the growth
of individual strains, with each repeat corresponding to a dif-
ferent sample of 12 strains with various susceptibility levels and
growth parameters (Fig. 3). Growth dynamics, both during and
after treatment, and the time taken by these individual strains
to regain the equilibrium were quite different in repetitions
(Fig. 3).
The overall variation across the sum of all susceptible and all
resistant strains was much less, as shown by the simulation enve-
lope (Fig. 4). All combinations of dosing factors resulted in a very
high resistant proportion at the end of treatment, irrespective of
the susceptibility levels of the strains (Fig. 4). Longer durations
of treatment clearly increase resistance levels, whereas changing
dosing frequencies appeared to result in almost no difference in
resistance. The difference in dosing duration resulted in various
lengths of time posttreatment to return to equilibrium (Fig. 4).
The resistance fractions were quantified at three time points (day
0, day maximum [max], and day 35) to expose the difference
between dosing protocols (Fig. 5).
The proportion of resistant counts was sensitive to the number
of competing strains (Fig. 6). A decrease in the number of com-
peting strains also decreased the time to reach equilibrium. The
difference in times was longer for longer treatment durations,
whereas the dosing frequency seemed to have no effect on the
differences in time (Fig. 7).
DISCUSSION
We developed a model that simulates how multiple bacterial
strains in a pig under different treatment protocols may compete.
The total population of strains was affected by different antimi-
crobial treatment protocols. We have demonstrated that the less
time the strains are under antimicrobial pressure, the less time it
takes for susceptible strains to overcome competition from the
resistant ones. In other words, given a constant daily dose, it is
better to treat for short periods with any dosing frequency. How-
ever, short treatment durations may not adequately treat the in-
fection, a factor to be considered in the treatment evaluations
(35). Variation in the total resistance level under the same treat-
ment is insensitive to the composition of the strains but sensitive
to the number of strains, with fewer strains resulting in a more
rapid return to equilibrium.
The effect of treating infections caused by bacterial pathogens
on the development and growth of antimicrobial resistance in
commensal bacteria is of considerable concern (35–38). High lev-
els of resistance are generally considered to be strongly correlated
with selection pressures fromantimicrobial use. Since treatment is
necessary on animal welfare grounds, careful investigation of dos-
FIG 4 Mean and simulation envelope of the total pool of susceptible (green) and total pool of resistant (red) bacterial counts from 100 repeats of a composition
with 12 strains at all nine combinations of treatments’ duration and dosing frequency, as given in Fig. 2.
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ing factors (dosing frequency, treatment duration, dose level, etc.)
could provide alternate treatment protocols to help reduce the
development of resistance. Here, we used a mathematical model
to investigate the relationship between dosing factors and resis-
tance levels in the presence of multiple competing strains. Limit-
ing growth factors were used in the model to reflect the in vivo
situation for dynamic equilibrium of multiple strains (30).
In contrast to most previous simulation studies, antimicrobial
pressure was not assumed to be constant during the treatment but
varied according to simulated plasma concentration-time profiles
FIG 5 Fraction of resistant counts at day 0 (before treatment), at “max” (i.e., the maximum fraction after treatment), and at day 35. Different dosing
frequencies—low (once every 2 days), normal (once a day), and high (twice a day)—are shown as subplots. Each color bar represents treatment duration.
FIG6 Fraction of total resistant counts at nine combinations of treatment factors where different colors represent the number of competing strains (i.e., 3, 6, and
12).
Multiple Bacterial Strain Model
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based on a two-compartment PKmodel (22–24). Key parameters
were estimated by fitting this model to the in vivo profile of tetra-
cycline plasma concentration in a pig following i.m. treatment,
derived from a previously published study (25). This approach
allows a subsequent PD model to reproduce realistic changes in
antimicrobial pressure in the pig. Treatment protocols that have
been investigated previously considered the effect of treatment on
a single or few clinical strains only, whereas we have shown here
that both the number of competing strains and the strain compo-
sition also have an impact on the evaluation of treatment proto-
cols. We considered the growth of multiple strains in our model
growing under dynamic equilibrium. This was achieved by intro-
ducing a double term including carrying capacity Nmax in equa-
tion 5, a formwhich differs from the very simple ratemodels. This
term is necessary, since the strain with the highest growth rate will
otherwise outgrow all of the other strains and equilibrium cannot
be established. A biological interpretation of the termsmay be that
the total population, Ni, cannot exceed Nmax because the total
nutrition present is limited, and it is assumed that a single strain
cannot utilize all types of nutrients and therefore cannot outgrow
all other strains. Furthermore, the growth parameters of compet-
ing strainswere estimated previously from in vitro growth,making
our study, to our knowledge, the first to include population rep-
resentative strains.
Our previous analysis of the growth of E. coli strains indicated
that there was no fitness cost to resistance (29). Thus, using these
population representative strains sets our model apart from pre-
vious models, which have assumed a fitness cost for resistant
strains. Mutation and conjugation mechanisms were not consid-
ered in the model, as they would be expected to have insignificant
effects compared to the already established resistance prior to
treatment. The plasma concentration of tetracycline was used in-
stead of the drug concentration at the interaction site since plasma
concentrations are considered an appropriate surrogatemarker in
most PK studies (39). A single pig treatment regardless of diseased
status of the pig was considered; thus, no transmission factors
were included in themodel, and themodel is consequently limited
to a single pig in isolation. The outflow rate was kept constant
throughout the investigated period, but in principle it could be
varying with the varying disease status of a pig.
We examined the competitive growth of E. coli strains, charac-
terized by their in vitro drug response, in a pig using in vivo drug
FIG 7 Resistance levels at three time points with day 0 (when treatment started), day “max” (the maximum resistance level), and day 35 (weaning end) for all
nine combination of dosing factors, with each color bar representing the number of competing strains.
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1640 aac.asm.org March 2015 Volume 59 Number 3Antimicrobial Agents and Chemotherapy
concentration profiles in plasma. The goal was to evaluate the
extent to which different dosing factors suppress the growth of
resistant strains when growing under dynamic equilibrium con-
ditions. Due to the competitive advantage of resistant strains, all
treatments showed an increase in resistance level, as shown in
previous studies (5, 11). Consequently, it would be preferable to
have less time under treatment to reduce the competitive growth
of these resistant strains. High peak concentrations may also lead
to high resistance levels at the end of treatment. All dosing proto-
cols showed rapid dominance of resistant strains during the treat-
ment, in agreement with results from other studies (11, 40). There
was a very small apparent effect of dosing frequency, whereas pre-
vious studies showed that an increased dosing frequency could
reduce resistance (15, 16, 36). This could have arisen because of
the large difference in MIC values of susceptible and resistant
strains (see the supplementalmaterial). Increased dosing frequen-
cies could not produce sufficiently high drug concentrations to
affect the resistant strains. Thus, adjusting the dosing frequency
does not seem to be an appropriate approach. A more prolonged
treatment resulted in a greater resistance and consequently took
longer to return to equilibrium. This is undesirable because the
longer the period before return to equilibrium, the greater the risk
of transmission of resistant strains to other pigs and humans, al-
though this has not been explicitly modeled in the present study.
In reality, treatment durations depend on the efficacy of the treat-
ment, but it may also be possible to reduce the duration with a
higher daily dose level to achieve the desired efficacy and lower
resistance levels (24). The effect of the number of strains on resis-
tance levels has not been investigated previously. Our results
indicate that the total resistant level is largely insensitive to
strain composition (Fig. 4) but that the number of competing
strains is an important determinant of the return time to equi-
librium (Fig. 7).
To conclude, the simulation model used in the present study
was used to investigate resistance dynamics under in vivo antimi-
crobial exposures. Short treatment duration resulted in the short-
est time for strains to return to equilibrium, while higher numbers
of competing strains substantially increased this time. Our predic-
tions have provided new insights into the relationship between
drug dosing factors and drug resistance. Specifically, we have
shown that both the dosing factors and the strain composition
have an impact on the resistance development, and taking these
into account could be helpful in the design of new treatment pro-
tocols.
The distribution of different strains may depend not only on
the pig but also on the herd or a section of a herd.When designing
the treatments, predictions from the present study could be used
to redesign the dosing regimens for i.m. injection treatments using
tetracycline in pigs. Moreover, accounting for the number of
strains and their compositionwould help to improve the design of
treatment protocols.
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